Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

Table 2 Inhaler technique, device mastery and device preference in the cross-sectional phase

Device mastery	Empty Spiromax (N = 481)	Empty Turbuhaler (N = 481)	Odds ratio (95% CI)^a	P-value
Step 1 (Intuitive use), n^b (%) [No. of patients participating]	160 (33.3) [481]	55 (11.4) [481]	4.89 (3.23–7.40)	< 0.001
Step 2 (Patient information leaflet), n^b (%) [No. of patients participating]	386 (80.2) [321]	308 (64.0) [426]	2.95 (2.06–4.22)	< 0.001
Step 3 (Instructional video), n^b (%) [No. of patients participating]	454 (94.4) [95]	418 (86.9) [173]	3.77 (2.05–6.95)	< 0.001
Achievement of dose preparation device mastery (primary endpoint; all patients), n (%)	468 (97.3)	443 (92.1)	4.12 (1.91–8.93)	< 0.001
Achievement of inhalation maneuver device mastery (all patients), n (%)	463 (96.3)	445 (92.5)	2.50 (1.28–4.88)	0.007
Number of steps taken to achieve device mastery, median (range)	1 (1–6)	2 (1–5)	N/A	< 0.001
Number of HCP-observed errors, median (range)	1.91 (0–6)	2.36 (0–6)	N/A	< 0.001
Patient device preference: PASAPQ score [scale of 1–100], median (range)	89.8^c (18.4–100)	85.7^c (14.3–100)	N/A	< 0.001

^aOdds ratios are derived from conditional logistic regression of data from paired patients
^bNumbers of patients achieving mastery at each stage are cumulative (i.e. patients achieving mastery at previous step(s) are included). Patients demonstrating mastery did not proceed to the next step; they were either proceeded to the second inhaler or finished the study (if they were using the second inhaler)
^cn = 477 for each. CI confidence interval, HCP, healthcare professional, N/A not applicable, PASAPQ Patient Satisfaction and Preference Questionnaire

ISSN: 1471-2466